Ternary Therapeutics Secures €4.1M for AI-Designed Molecular Glues
Belgium-based biotech startup Ternary Therapeutics has raised €4.1 million to advance an AI-driven platform that designs so‑called molecular glues, a new class of small molecules aimed at turning previously “undruggable” proteins into viable therapeutic targets.
The investment underscores growing confidence in combining artificial intelligence with next-generation drug discovery tools to address complex diseases that have resisted conventional treatments.
Targeting the “Undruggable” with Molecular Glues
Traditional small-molecule drugs typically bind to a single protein to block or modulate its activity. Many disease-driving proteins, however, lack the structural pockets that classic drugs require, earning them the label “undruggable.” Molecular glues offer a different strategy: they promote selective interactions between proteins, effectively “gluing” them together so that the cell’s own machinery can degrade or rewire harmful targets.
Ternary Therapeutics is building an integrated platform that uses AI algorithms to predict which protein pairs can be bridged by small molecules and how those molecules should be designed. By modeling protein–protein interactions and ternary complexes at scale, the company aims to generate drug candidates with higher precision and lower development risk.
AI-First Platform for Drug Discovery
The newly raised €4.1 million seed round will fund expansion of the company’s computational engine, in‑house chemistry, and early preclinical pipeline. The platform combines large-scale biological datasets, structural modeling, and generative machine learning to propose, score, and optimize molecular glues in silico before moving them into laboratory validation.
By front‑loading design with AI-driven predictions, Ternary Therapeutics aims to shorten discovery timelines and reduce the attrition that has historically slowed biotech innovation. The company is expected to focus initially on oncology and immune-related disorders, where undruggable targets are especially prevalent.
Positioning Europe in Next-Gen Drug Discovery
The funding round highlights Europe’s growing role in AI-powered drug discovery, a field increasingly dominated by startups that merge deep computational expertise with advanced biology. As investors seek scalable platforms rather than single-asset plays, Ternary Therapeutics is positioning itself as a key player in the emerging molecular glue landscape, with potential applications across multiple therapeutic areas.